GlassScriptPhysician profile
Amr Etman
NPI 1932362985
$433.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $288 · 2021: $125 · 2022: $20.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $85.41 | 2020-2021 | |
| Corcept Therapeutics | $79.63 | 2020 | |
| Novo Nordisk INC | $47.95 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $37.71 | 2021 | |
| Ibsa Pharma INC. | $34.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.60 | 2020 | |
| Genzyme Corporation | $26.77 | 2020 | |
| Sk Life Science, INC. | $20.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.63 | 2020 | |
| Coopersurgical, INC. | $20.58 | 2022 | |
| Abbott Laboratories | $17.66 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Etman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.